Sanofi - ADR (SNY): Price and Financial Metrics

Sanofi - ADR (SNY): $37.25

-1.15 (-2.99%)

POWR Rating

Component Grades














  • Value is the dimension where SNY ranks best; there it ranks ahead of 94.85% of US stocks.
  • SNY's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • SNY ranks lowest in Momentum; there it ranks in the 17th percentile.

SNY Stock Summary

  • SNY has a higher market value than 98.07% of US stocks; more precisely, its current market capitalization is $103,157,095,140.
  • With a year-over-year growth in debt of -26.85%, SANOFI's debt growth rate surpasses only 12.51% of about US stocks.
  • Revenue growth over the past 12 months for SANOFI comes in at -4.24%, a number that bests just 17.81% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to SANOFI, a group of peers worth examining would be DE, CAT, GILD, NFLX, and RTX.
  • SNY's SEC filings can be seen here. And to visit SANOFI's official web site, go to

SNY Stock Price Chart Interactive Chart >

Price chart for SNY

SNY Price/Volume Stats

Current price $37.25 52-week high $58.10
Prev. close $38.40 52-week low $36.91
Day low $36.91 Volume 6,805,600
Day high $37.63 Avg. volume 2,418,576
50-day MA $43.97 Dividend yield 3.28%
200-day MA $49.92 Market Cap 94.43B

Sanofi - ADR (SNY) Company Bio

Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.

SNY Latest News Stream

Event/Time News Detail
Loading, please wait...

SNY Latest Social Stream

Loading social stream, please wait...

View Full SNY Social Stream

Latest SNY News From Around the Web

Below are the latest news stories about SANOFI that investors may wish to consider to help them evaluate SNY as an investment opportunity.

Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors

The FDA grants approval to Lilly's (LLY) Retevmo in advanced or metastatic solid tumors with a RET gene fusion. It converts the drug's accelerated approval in NSCLC indication to full approval.

Yahoo | September 22, 2022

Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent

Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.

Yahoo | September 22, 2022

AstraZeneca (AZN) Gets EU Nod for Evusheld to Treat COVID

Following the label expansion approval in the European Union, Evusheld is currently the only long-acting antibody combination available for both prevention and treatment of COVID-19.

Yahoo | September 21, 2022

AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication

The CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug is approved for treating plaque psoriasis and psoriatic arthritis indications.

Yahoo | September 20, 2022

Sanofi (SNY) Moves to Buy: Rationale Behind the Upgrade

Sanofi (SNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | September 20, 2022

Read More 'SNY' Stories Here

SNY Price Returns

1-mo -8.75%
3-mo -29.28%
6-mo -25.69%
1-year -20.72%
3-year -13.24%
5-year -10.28%
YTD -23.85%
2021 5.87%
2020 -0.83%
2019 23.73%
2018 4.20%
2017 8.73%

SNY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full SNY Dividend History

Continue Researching SNY

Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:

Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7417 seconds.